Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764851 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates
A Phase 1 study, sponsored by Emalex Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04764851: Clinical Trial Phase 1 study, sponsored by Emalex Biosciences.
NCT04764851 is a Phase 1 study that was terminated before completion, run by Emalex Biosciences. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04764851, a Phase 1 study, was terminated before completion, sponsored by Emalex Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
Primary Outcome
Up to 38 blood samples will be collected at the indicated time points for pharmacokinetic analysis
Interventions
- DRUG ecopipam HCl ~2mg/kg/day
- COMBINATION_PRODUCT Cohort 1 Probe Cocktail
- COMBINATION_PRODUCT Cohort 2 Probe Cocktail
- COMBINATION_PRODUCT Cohort 3 Probe Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2021-05-07 |
| Phase | Phase 1 |
Why NCT04764851 stopped before completion
NCT04764851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 4 interventions - of which ecopipam HCl ~2mg/kg/day is the first listed.
NCT04764851 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04764851 about?
NCT04764851 is a clinical study titled "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates". This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
What is the current status of trial NCT04764851?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-02-18. Estimated completion is 2021-05-07.
What interventions are being tested in trial NCT04764851?
The interventions under investigation include: ecopipam HCl ~2mg/kg/day (DRUG), Cohort 1 Probe Cocktail (COMBINATION_PRODUCT), Cohort 2 Probe Cocktail (COMBINATION_PRODUCT), Cohort 3 Probe Cocktail (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04764851?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04764851's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI